(BSTZ) BlackRock Science - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260K1016

Stock: Equity, Technology, Growth, Global

Total Rating 43

Risk 75

Buy Signal 0.04

Asset Management » Asset Management & Custody Banks
Age: 6.6y

Market Cap: 1,594m
Avg Trading Vol: 6.12M USD

ATR: 2.03%
Peers RS (IBD): 76.67

EPS (Earnings per Share)

EPS CAGR: -55.12%
EPS Trend: -86.3%

Last SUE: -0.19
Qual. Beats: 0

Revenue

Rev. CAGR: -13.96%
Rev. Trend: -20.4%

Qual. Beats: 0

Dividends

Dividend Yield	13.31%
Yield on Cost 5y	13.50%
Yield CAGR 5y	-2.22%
Payout Consistency	93.3%
Payout Ratio	42.1%

Risk 5d forecast
Volatility	21.9%
Relative Tail Risk	1.35%

Reward TTM
Sharpe Ratio	0.66
Alpha	3.73

Character TTM
Beta	0.976
Beta Downside	0.899

Drawdowns 3y
Max DD	25.31%
CAGR/Max DD	0.79

Description: BSTZ BlackRock Science January 15, 2026

BlackRock Science and Technology Trust II (NYSE: BSTZ) is a closed-ended equity fund launched in June 2019 and domiciled in the United States. Managed by BlackRock Advisors, LLC, the vehicle allocates capital to publicly traded companies worldwide that operate within the science and technology arena, with a focus on growth-oriented stocks across all market-cap tiers.

Key metrics as of the most recent filing show roughly $1.2 billion in assets under management and an expense ratio of 0.85 %. The fund’s performance has been closely tied to macro drivers such as global R&D spending, which grew 5 % YoY in 2023, and the ongoing semiconductor shortage that continues to buoy chip-makers’ valuations. Additionally, the rapid adoption of artificial-intelligence applications across enterprise software and biotech pipelines has been a primary catalyst for the fund’s top-line growth.

For a deeper quantitative breakdown, you might explore ValueRay’s analytics platform to see how BSTZ’s risk-adjusted returns compare to sector peers.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income: 372.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA -2.57 > 1.0
NWC/Revenue: -3.95% < 20% (prev 5.25%; Δ -9.20% < -1%)
CFO/TA -0.08 > 3% & CFO -130.6m > Net Income 372.2m
Net Debt (-100.4k) to EBITDA (372.2m): -0.00 < 3
Current Ratio: 0.34 > 1.5 & < 3
Outstanding Shares: last quarter (68.7m) vs 12m ago 105.9% < -2%
Gross Margin: 90.18% > 18% (prev 0.40%; Δ 8977 % > 0.5%)
Asset Turnover: 21.08% > 50% (prev 5.57%; Δ 15.51% > 0%)
Interest Coverage Ratio: 8.77 > 6 (EBITDA TTM 372.2m / Interest Expense TTM 21.1k)

Altman Z'' 10.00

A: -0.01 (Total Current Assets 6.06m - Total Current Liabilities 17.6m) / Total Assets 1.60b
B: 0.36 (Retained Earnings 578.5m / Total Assets 1.60b)
C: 0.00 (EBIT TTM 185.4k / Avg Total Assets 1.39b)
D: 24.69 (Book Value of Equity 1.53b / Total Liabilities 62.1m)
Altman-Z'' Score: 27.06 = AAA

What is the price of BSTZ shares?

As of February 08, 2026, the stock is trading at USD 22.56 with a total of 225,137 shares traded.
Over the past week, the price has changed by +0.80%, over one month by -0.91%, over three months by +4.20% and over the past year by +18.33%.

Is BSTZ a buy, sell or hold?

BlackRock Science has no consensus analysts rating.

What are the forecasts/targets for the BSTZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	-	-
Analysts Target Price	-	-
ValueRay Target Price	26	15.4%

BSTZ Fundamental Data Overview February 04, 2026

P/E Trailing = 3.635
P/S = 11.5195
P/B = 1.0263
Revenue TTM = 293.2m USD
EBIT TTM = 185.4k USD
EBITDA TTM = 372.2m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 27.9m USD (from shortTermDebt, last quarter)
Debt = 27.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -100.4k USD (from netDebt column, last quarter)
Enterprise Value = 1.62b USD (1.59b + Debt 27.9m - CCE 100.4k)
Interest Coverage Ratio = 8.77 (Ebit TTM 185.4k / Interest Expense TTM 21.1k)
EV/FCF = -16.12x (Enterprise Value 1.62b / FCF TTM -100.6m)
FCF Yield = -6.21% (FCF TTM -100.6m / Enterprise Value 1.62b)
FCF Margin = -34.33% (FCF TTM -100.6m / Revenue TTM 293.2m)
Net Margin = 127.0% (Net Income TTM 372.2m / Revenue TTM 293.2m)
Gross Margin = 90.18% ((Revenue TTM 293.2m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = 92.32% (prev 92.85%)
Tobins Q-Ratio = 1.02 (Enterprise Value 1.62b / Total Assets 1.60b)
Interest Expense / Debt = 0.08% (Interest Expense 21.1k / Debt 27.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = 146.5k (EBIT 185.4k * (1 - 21.00%))
Current Ratio = 0.34 (Total Current Assets 6.06m / Total Current Liabilities 17.6m)
Debt / Equity = 0.02 (Debt 27.9m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = -0.00 (Net Debt -100.4k / EBITDA 372.2m)
Debt / FCF = 0.00 (negative FCF - burning cash) (Net Debt -100.4k / FCF TTM -100.6m)
Total Stockholder Equity = 1.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.77% (Net Income 372.2m / Total Assets 1.60b)
RoE = 27.29% (Net Income TTM 372.2m / Total Stockholder Equity 1.36b)
RoCE = 0.01% (EBIT 185.4k / Capital Employed (Equity 1.36b + L.T.Debt 0.0))
RoIC = 0.01% (NOPAT 146.5k / Invested Capital 1.38b)
WACC = 9.35% (E(1.59b)/V(1.62b) * Re(9.51%) + D(27.9m)/V(1.62b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 41.49%
Fair Price DCF = unknown (Cash Flow -100.6m)
EPS Correlation: -86.26 | EPS CAGR: -55.12% | SUE: -0.19 | # QB: 0
Revenue Correlation: -20.45 | Revenue CAGR: -13.96% | SUE: N/A | # QB: 0

Additional Sources for BSTZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle